mFOLFOX6

Phase 2

Aveo Pharmaceuticals, Inc. (AVEO)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Colorectal Cancer

SLDBFrog Bacterium Therapy

BNTXautogene cevumeran

Phase 2

View Full Landscape

Drug Information

Target Indication

Colorectal Cancer

Clinical Trial

NCT01478594

Last updated: 1/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AVEO

Aveo Pharmaceuticals, Inc.

Healthcare•North America•NASDAQ

Related Pipeline

Tivozanib hydrochloridePhase 3

Carcinoma, Renal Cell

FiclatuzumabPhase 3

Metastatic Head-and-neck Squamous-cell Carcinoma

TivozanibPhase 3

Renal Cell Carcinoma

tivozanib (AV-951)Phase 3

Advanced Renal Cell Carcinoma

Samalizumab (BAML-16-001-S1)Phase 3

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts